Specifically, we investigated whether, subsequent to adjusting for other clinical factors such as albuminuria, TNF-α and NGAL were able to provide additional prognostic information with regard to the progression of DN at the early stage. This evidence concerns the gene LCN2 and liver dysplastic nodule.